Novel therapeutics in hypertriglyceridemia
The DOI matches its Crossref record; 57 of the 59 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
PURPOSE OF REVIEW: We provide an overview of recent advances in the therapy of hypertriglyceridemia, focusing on several new therapies with potential for treating of familial chylomicronemia, other forms of hypertriglyceridemia, and for triglyceride-lowering in patients with other lipid disorders. RECENT FINDINGS: Newer triglyceride-lowering modalities under evaluation include gene therapy for lipoprotein lipase deficiency (alipogene tiparvovec), and antisense oligonucleotides against mRNA for apolipoproteins B (mipomersen) and C3 (volanesorsen, ISIS 304801). Other potential therapies include small molecule inhibitors of microsomal triglyceride transfer protein (lomitapide) and diacylglycerol acyltransferase-1 (pradigastat), and a monoclonal antibody against angiopoietin-like protein 3 (REGN1500). There is also renewed interest in omega-3 fatty acids, and in developing potent and selective agonists of peroxisome proliferator-activated receptors. SUMMARY: Several promising triglyceride-lowering therapies are at various stages of development; a few are even available in some markets. Although existing data suggest good biochemical efficacy, data on long-term clinical outcomes are still limited. For some therapies, cost will be an important consideration, and use will likely be restricted to orphan indications, for example very severe cases of hypertriglyceridemia as seen in familial chylomicronemia syndrome, although some therapies could theoretically be more broadly used one day for cardiovascular disease prevention.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Apo C-III is expressed both intestinally and hepatically, circulates with TG-rich lipoproteins, has net deleterious effects on lipoprotein metabolism58–63”
From Clinical review on triglycerides (2020) · cites this paper as [58]
In the citing paper
“Pradigastat (Novartis) and AZD7687 (AstraZeneca) are oral inhibitors of intestinal DGAT1, which governs dietary fat absorption and TG synthesis.58”
From Clinical review on triglycerides (2020) · cites this paper as [58]
In the citing paper
“Volanesorsen (Waylivra; ISIS 304801 or IONIS-APOCIIIRx; Ionis/Akcea), a subcutaneously injected second-generation 2'-O-methoxyethyl chimeric antisense inhibitor, impairs translation of apolipoprotein (apo) C-III mRNA.58,67”
From Clinical review on triglycerides (2020) · cites this paper as [58]
Citations
Cites
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881 · cited 1×
“When compared head-tohead with placebo in randomized controlled trials, fibrates reduce CVD risk by approximately 20% [13], particularly in patients with high triglyceride and low HDL cholesterol [14].”
BackgroundRubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439 · cited 1×
“When compared head-tohead with placebo in randomized controlled trials, fibrates reduce CVD risk by approximately 20% [13], particularly in patients with high triglyceride and low HDL cholesterol [14].”
BackgroundNiacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837 · cited 1×
“But the incremental benefit of fibrates in CVD risk reduction vanishes with background statin therapy [15], although subgroup analyses suggest that fibrates may have some incremental benefit in patients with triglyceride more than 2.”
BackgroundMajor lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296
Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin
Canner, P. L., Berge, K. G., Wenger, N. K., Stamler, J., Friedman, L., Prineas, R. J., & Friedewald, W. (1986) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(86)80293-5 · Cited by 1,824 · cited 1×
“Niacin has somewhat less of a triglyceride-lowering effect than fibrates, and like fibrates, monotherapy with niacin is associated with significant reductions in CVD events and mortality [17].”
BackgroundHokanson, J. E., & Austin, M. A. (1996) · Journal of Cardiovascular Risk · doi:10.1097/00043798-199604000-00014 · Cited by 1,706 · cited 1×
“Some meta-analyses of epidemiologic studies that have endeavored to adjust for low HDL cholesterol showed that elevated triglyceride levels are independently associated with CVD risk [1] whereas others have not [2].”
BackgroundEffects of extended-release niacin with laropiprant in high-risk patients
The HPS2-THRIVE Collaborative Group (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300955 · Cited by 1,668
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Sabatine, M. S., Giugliano, R. P., Wiviott, S. D., Raal, F. J., Blom, D. J., Robinson, J., Ballantyne, C. M., Somaratne, R., Legg, J., Wasserman, S. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500858 · Cited by 1,509
Research works printed but not linked: 2
- Pirillo, 2015, Drug Des Devel Ther, 9, 2129
- Goldberg, 2012, Drug Des Devel Ther, 6, 251
Cited by
Clinical review on triglycerides
Laufs, U., Parhofer, K. G., Ginsberg, H. N., & Hegele, R. A. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz785 · Cited by 544
“58,67 In a Phase 2 trial of volanesorsen, 300mg given weekly to HTG patients (NCT01529424), TG levels were reduced by 80%.”
BackgroundSelf-citationHypertriglyceridemic pancreatitis: Epidemiology, pathophysiology and clinical management
de Pretis, N., Amodio, A., & Frulloni, L. (2018) · United European Gastroenterology Journal · doi:10.1177/2050640618755002 · Cited by 265
“, Amsterdam, Netherlands).(46) A meta-analysis of eight randomized, controlled trials involving patients with dyslipidemia showed that treatment with mipomersen significantly reduced serum triglyceride levels compared with placebo ( p< 0.”
BackgroundManagement of Hypertriglyceridemia Induced Acute Pancreatitis
Garg, R., & Rustagi, T. (2018) · BioMed Research International · doi:10.1155/2018/4721357 · Cited by 249
“Newer triglyceride-lowering modalities under evaluation and at different stages of development include gene therapy for lipoprotein lipase deficiency (alipogene tiparvovec, and antisense oligonucleotides against mRNA for apolipoproteins B (mipomersen) and C3 (volanesorsen, ISIS 304801), diacylglycerol acyltransferase-…”
BackgroundRole of lipoprotein lipase in lipid metabolism
Olivecrona, G. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000297 · Cited by 189
Lipid-Lowering Agents: Targets Beyond PCSK9
Hegele, R. A., & Tsimikas, S. (2019) · Circulation Research · doi:10.1161/circresaha.118.313171 · Cited by 171
“Older Approaches to Lowering TG: Fibrates and Omega-3 Preparations Fibrates are agonists of PPAR-α that lower TGs and raise HDL-C.(78) These include gemfibrozil, fenofibrate, and bezafibrate,(78) which have guideline indications for reductions of severely elevated TG levels to reduce pancreatitis risk.”
BackgroundInfluentialSelf-citation
Metadata
- Authors
- Gryn, S. E., & Hegele, R. A.
- Affiliations
- Western University (CA)
- Corresponding author
- Gryn, Steven E.
- Venue
- Current Opinion in Lipidology
- Published
- 2015-12
- Volume
- 26
- Issue
- 6
- Pages
- 484-491
- ISSN
- 0957-9672 (ISSN-L)
- OpenAlex
- W2415852003
- Cited by
- 44
- References
- 59
- Citations by year
- 2026: 1 · 2024: 3 · 2023: 5 · 2022: 1 · 2021: 5 · 2020: 3 · 2019: 9 · 2018: 4 · 2017: 5 · 2016: 8
- FWCI
- 0.97
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Opinion in Lipidology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Amgen
- Pfizer
- AstraZeneca
- Canadian Institutes of Health Research (79523_1, MOP13430)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- hypertriglyceridemia, familial chylomicronemia syndrome, triglyceride-lowering therapy, lipoprotein lipase deficiency, antisense oligonucleotides, mipomersen, volanesorsen, microsomal triglyceride transfer protein inhibitor, lomitapide, ANGPTL3, omega-3 fatty acids, peroxisome proliferator-activated receptor agonists, apolipoprotein B, apolipoprotein C-III
- MeSH terms
- Animals, Hypolipidemic Agents, Humans, Hypertriglyceridemia, Genetic Therapy, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Novel therapeutics in hypertriglyceridemia. https://app.cochat.ai/papers/10.1097/mol.0000000000000231
- The paper
- Gryn, S. E., & Hegele, R. A. (2015). Novel therapeutics in hypertriglyceridemia. Current Opinion in Lipidology. https://doi.org/10.1097/mol.0000000000000231
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.